Skip to main content

Table 1 Patients characteristics. NSCLC (Non Small Cell Lung Cancer); SD (Stability of Disease); PR (Partial Response); CR (Complete Response)

From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

 

Patients

N = 318 (%)

Age (years)

 Median (range)

68.6 (32–90)

Gender

 M

223 (70.13)

 F

95 (29.87)

Histology

 NSCLC

200 (62.89)

 Melanoma

87 (27.36)

 Kidney

23 (7.23)

 Others

8 (2.52)

ECOG PS

 0

199 (62.58)

 1

102 (32.07)

 ≥ 2

17 (5.35)

Number of metastatic sites

 < 3

214 (67.3)

 ≥ 3

104 (32.7)

Metastasis

 CNS

40 (12.58)

 Bone

60 (18.87)

 Liver

28 (8.81)

Previous lines of treatments

 0

122 (38.37)

 1

126 (39.62)

 ≥ 2

70 (22.01)

Immunotherapeutic agents

 Pembrolizumab

126 (39.62)

 Nivolumab

187 (58.81)

 Atezolizumab

5 (1.57)

Duration of Immunotherapy

 ≥ 12 months < 18

121 (38.05)

 ≥ 18 months < 24

94 (29.56)

 ≥ 24 months < 36

80 (25.16)

 ≥ 36 months

23 (7.23)

Best response

 SD

88 (27.67)

 PR

197 (61.95)

 CR

33 (10.38)